

## ABB1004 TO THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Wilfried M. Braje, et al.	)	Group Art Unit: 1614
Serial No.	: 10/823,317	)	Examiner:
Filing Dat	e: April 13, 2004	)	
	[Piperazinyl)hetaryl]arylsulfonamide empounds	) )	

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Attached Form PTO/1449A lists references that were cited in the International Search
Report of the corresponding PCT application and which may be considered to be material to the
bove-identified application by the Patent Examiner. Copies of the references are enclosed.

Entry into the record is respectfully requested.

If any additional fee might be required in connection with this matter, please charge our Deposit Account No. 23-0785.

Respectfully submitted,

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER

Martin L. Katz, Res. No. 25.01

January 19, 2005

Citicorp Center, Suite 3800 500 West Madison Street



## 37 CFR 1.8 CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service, as First Class Mail in an envelope addressed to: Commissioner for Patents, Alexandria, Virginia 22313-1450 on January 19, 2005

Rebecca J. Willis

Comparable to Form PTO SB 08A (08-03) Approved for use through 07 31 2006. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Patent DepartMENT OF COMMERCE

Patent DepartMENT OF COMMERCE

Patent Depar

ans.	Under the	Paperwork Redi	ection Act of 1995	, no persons a	ire required to respond to a confection	n of information unless it displays a valid ONB conditi numbe
HAI.					Application Number	10/823,317
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)	Filing Date	January 19, 2005				
TA TRADELLINEC	SUPPLEMENTAL NFORMATION DISCLOSURE TATEMENT BY APPLICANT (Use as many sheets as necessary)	First Named Inventor	Wilfried M. Braje, et al.			
					Group Art Unit	1614
(Use as many sheets as necessary)					Examiner Name	
	Sheet	1	of	2	Attorney Docket No.	ABB10043P0012US

			U.S. PATENT D	OCUMENTS	
Examiner	Cite	U.S. Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
Initials* No.1	Number Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	r assages of Relevant rigules Appear	
		US-			
-		US-			
		US-			

		FOREIGN PA	ATENT DOCUMENT	s			<u></u>
	Cite	Foreign Patent Document	Publication Date		of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	MM-DD-YYYY Applicant of Cited Document		or Relevant Figures Appear	
		WO 2004/058265 A	July 15, 2004	BIOF	OCUS PLC		
						<u> </u>	
Examiner Si	anature				Date Conside	red	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 'Benter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'S Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. 'Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO TIIIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Compareble to Form P1O SE 38A (68-63 Approved for use through 0731 2006 OMB 0651-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

required to respond to a collection of	information unless it displays a valid OMB control number
Application Number	10/823,317
Filing Date	January 19, 2005
First Named Inventor	Wilfried M. Braje, et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket No.	ABB10043P0012US

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and page (s),		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		DATABASE CHEMCATS, Chemical Abstracts Service, Columbus, Ohio, US; XP002294060	
		WILLECOMME, B.: Recherches dans la série de la pipérizine; Annales de Chimie, Vol. 4, No. 6, 1969, pages 405-428, XP009035691	
		BROMIDGE et al; "5-Chloro-N-(4-methoxy-3-piperazine-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): A Potent, Selective, and Orally Bioavailable 5-HT6 Receptor Antagonist"; Journal of Medicinal Chemistry, American Chemican Society, Washington, D.C. US, Vol. 42, No. 2, 28 January 1999 (1999-01-28), pages 202-205, XP002109186; ISSN: 0022-2623	
		BROMIDGE, S.M. et al; "Novel (4-piperazin-1-ylquinolin-6-yl) arylsulfonamides with high affinity and selectivity for the 5-HT6 receptor"; BIOORG. MED. CHEM. LETT., Vol. 11, 2001, pages 2843-2846, XP002294076	
			_
-			
Examiner Sign	nature	Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.